A PYMNTS Company

EU: Pay-for-delay lands drug makers with $580 million in fines

By  |  July 9, 2014

The European Commission issued hundreds of millions of dollars on pharmaceutical makers including France’s Servier for pay-for-delay deals that were found to have distorted the market, according to reports.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Servier and five generic drug makers were fined a combined $580 million for colluding to prevent generic and cheaper forms of medication from hitting store shelves in deals known as pay-for-delay. The medicine under scrutiny is Perindopril, which is used to treat blood pressure issues.

    The collusion lead to Servier “systematically buying out any competitive threats,” said European Commissioner Joaquin Almunia, who also called the actions “clearly anticompetitive and abusive.”

    Servier itself must pay $450 million, reports said.

    Full content: ABC News

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.